pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

20,113 catalysts · 18,987 approval · 7,208 phase readout · 5,000 device 510k · 4,728 grant · 3,603 8k filing · 2,000 device pma

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 1 catalyst2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts2026-11-09: 1 catalyst2026-11-10: 0 catalysts2026-11-11: 0 catalysts2026-11-12: 0 catalysts2026-11-13: 0 catalysts2026-11-14: 0 catalysts2026-11-15: 0 catalysts2026-11-16: 0 catalysts2026-11-17: 0 catalysts2026-11-18: 0 catalysts2026-11-19: 0 catalysts2026-11-20: 0 catalysts2026-11-21: 0 catalysts2026-11-22: 0 catalysts
view
agendamonth
hide past →
sort
soonestlatesttypesponsoralpha
type: recall×type: approval×clear all
type
  • approval18,987
  • phase readout7,208
  • device 510k5,000
  • grant4,728
  • 8k filing3,603
  • device pma2,000
  • device recall
2,000
  • recall1,126
  • device adverse event1,000
  • earnings585
  • therapy area

    no tagged catalysts yet

    Week of Oct 13, 2025

    29
    ›Oct 16, 2025approval318d agoAMJEVITA (ADALIMUMAB-ATTO) — FDA approvalAMJEVITA

    Sponsor: AMGEN INC. Form: INJECTABLE. Route: INJECTION

    full page →AMJEVITA →fda approvals ↗
    ›Oct 16, 2025approval318d agoTRIMETHOBENZAMIDE HYDROCHLORIDE — FDA approvalGavis Pharmaceuticals LLC

    Sponsor: BPI LABS. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Oct 16, 2025approval318d agoCYLTEZO (ADALIMUMAB-ADBM) — FDA approvalCYLTEZO

    Sponsor: BOEHRINGER INGELHEIM. Form: INJECTABLE. Route: INJECTION

    full page →CYLTEZO →fda approvals ↗
    ›Oct 16, 2025approval318d agoHYRIMOZ (ADALIMUMAB-ADAZ) — FDA approvalHYRIMOZ

    Sponsor: SANDOZ INC. Form: INJECTABLE. Route: INJECTION

    full page →HYRIMOZ →fda approvals ↗
    ›Oct 16, 2025approval318d agoZTALMY (GANAXOLONE) — FDA approvalganaxolone

    Sponsor: IMMEDICA PHARMA. Form: SUSPENSION. Route: ORAL

    full page →ganaxolone →fda approvals ↗
    ›Oct 16, 2025approval318d agoZTALMY (GANAXOLONE) — FDA approvalganaxolone

    Sponsor: IMMEDICA PHARMA. Form: SUSPENSION. Route: ORAL

    full page →ganaxolone →fda approvals ↗
    ›Oct 16, 2025approval318d agoFERABRIGHT (FERUMOXYTOL) — FDA approvalCovis Pharma BV

    Sponsor: COVIS. Form: SOLUTION. Route: INTRAVENOUS

    full page →fda approvals ↗
    ›Oct 16, 2025approval318d agoSOJOURN (SEVOFLURANE) — FDA approvalSEVOFLURANE

    Sponsor: PIRAMAL CRITICAL. Form: LIQUID. Route: INHALATION

    full page →SEVOFLURANE →fda approvals ↗
    ›Oct 16, 2025approval318d agoYUFLYMA (ADALIMUMAB-AATY) — FDA approvalYUFLYMA

    Sponsor: CELLTRION. Form: INJECTABLE. Route: INJECTION

    full page →YUFLYMA →fda approvals ↗
    ›Oct 17, 2025approval317d agoVYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC) — FDA approvalARGENX SE

    Sponsor: ARGENX BV. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Oct 17, 2025approval317d agoOZEMPIC (SEMAGLUTIDE) — FDA approvalNovo Nordisk AS

    Sponsor: NOVO. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Oct 17, 2025approval317d agoOZEMPIC (SEMAGLUTIDE) — FDA approvalNovo Nordisk AS

    Sponsor: NOVO. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Oct 17, 2025approval317d agoOZEMPIC (SEMAGLUTIDE) — FDA approvalNovo Nordisk AS

    Sponsor: NOVO. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Oct 17, 2025approval317d agoOXYMORPHONE HYDROCHLORIDE — FDA approvalAmneal Pharmaceuticals, Inc.

    Sponsor: IMPAX LABS. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Oct 17, 2025approval317d agoGAZYVA (OBINUTUZUMAB) — FDA approvalobinutuzumab

    Sponsor: GENENTECH. Form: INJECTABLE. Route: INJECTION

    full page →obinutuzumab →fda approvals ↗
    ›Oct 17, 2025approval317d agoGAZYVA (OBINUTUZUMAB) — FDA approvalobinutuzumab

    Sponsor: GENENTECH. Form: INJECTABLE. Route: INJECTION

    full page →obinutuzumab →fda approvals ↗
    ›Oct 17, 2025approval317d agoBALVERSA (ERDAFITINIB) — FDA approvalerdafitinib

    Sponsor: JANSSEN BIOTECH. Form: TABLET. Route: ORAL

    full page →erdafitinib →fda approvals ↗
    ›Oct 17, 2025approval317d agoTEZSPIRE (TEZEPELUMAB-EKKO) — FDA approvaltezepelumab

    Sponsor: ASTRAZENECA AB. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →tezepelumab →fda approvals ↗
    ›Oct 17, 2025approval317d agoHADLIMA (ADALIMUMAB-BWWD) — FDA approvalHADLIMA

    Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTABLE. Route: INJECTION

    full page →HADLIMA →fda approvals ↗
    ›Oct 17, 2025approval317d agoCLOMIPHENE CITRATE — FDA approvalCLOMIPHENE CITRATE

    Sponsor: NOVITIUM PHARMA. Form: TABLET. Route: ORAL

    full page →CLOMIPHENE CITRATE →fda approvals ↗
    ›Oct 17, 2025approval317d agoTRIAMCINOLONE ACETONIDE — FDA approvaltriamcinolone acetonide Rising

    Sponsor: ALEMBIC. Form: INJECTABLE. Route: INJECTION

    full page →triamcinolone acetonide Rising →fda approvals ↗
    ›Oct 17, 2025approval317d agoBUCAPSOL (BUSPIRONE HYDROCHLORIDE) — FDA approvalBUSPIRONE HYDROCHLORIDE

    Sponsor: EPIC PHARMA LLC. Form: CAPSULE. Route: ORAL

    full page →BUSPIRONE HYDROCHLORIDE →fda approvals ↗
    ›Oct 17, 2025approval317d agoEPIOXA HD/EPIOXA KIT (RIBOFLAVIN 5'-PHOSPHATE SODIUM) — FDA approvalriboflavin 5'-phosphate sodium

    Sponsor: GLAUKOS. Form: SOLUTION/DROPS. Route: OPHTHALMIC

    full page →riboflavin 5'-phosphate sodium →fda approvals ↗
    ›Oct 17, 2025approval317d agoPOMALIDOMIDE — FDA approvalPOMALIDOMIDE

    Sponsor: MYLAN. Form: CAPSULE. Route: ORAL

    full page →POMALIDOMIDE →fda approvals ↗
    ›Oct 17, 2025approval317d agoVYVGART (EFGARTIGIMOD ALFA) — FDA approvalARGENX SE

    Sponsor: ARGENX BV. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Oct 17, 2025approval317d agoTACROLIMUS — FDA approvaltacrolimus ER

    Sponsor: GLENMARK PHARMS LTD. Form: CAPSULE. Route: ORAL

    full page →tacrolimus ER →fda approvals ↗
    ›Oct 17, 2025approval317d agoTACROLIMUS — FDA approvaltacrolimus ER

    Sponsor: GLENMARK PHARMS LTD. Form: CAPSULE. Route: ORAL

    full page →tacrolimus ER →fda approvals ↗
    ›Oct 17, 2025approval317d agoTACROLIMUS — FDA approvaltacrolimus ER

    Sponsor: GLENMARK PHARMS LTD. Form: CAPSULE. Route: ORAL

    full page →tacrolimus ER →fda approvals ↗
    ›Oct 17, 2025approval317d agoTACROLIMUS — FDA approvaltacrolimus ER

    Sponsor: GLENMARK PHARMS LTD. Form: CAPSULE. Route: ORAL

    full page →tacrolimus ER →fda approvals ↗

    Week of Oct 20, 2025

    21
    ›Oct 20, 2025approval314d agoBEYFORTUS (NIRSEVIMAB-ALIP) — FDA approvalnirsevimab

    Sponsor: ASTRAZENECA AB. Form: INJECTABLE. Route: INJECTION

    full page →nirsevimab →fda approvals ↗
    ›Oct 20, 2025approval
    ← prev
    page 351 of 403
    next →
    314d ago
    PROPARACAINE HYDROCHLORIDE — FDA approvalPROPARACAINE HYDROCHLORIDE

    Sponsor: MICRO LABS. Form: SOLUTION/DROPS. Route: OPHTHALMIC

    full page →PROPARACAINE HYDROCHLORIDE →fda approvals ↗
    ›Oct 20, 2025approval314d agoVANRAFIA (ATRASENTAN HYDROCHLORIDE) — FDA approvalatrasentan hydrochloride

    Sponsor: NOVARTIS. Form: TABLET. Route: ORAL

    full page →atrasentan hydrochloride →fda approvals ↗
    ›Oct 21, 2025approval313d agoTRAMADOL HYDROCHLORIDE — FDA approvalTrigen Laboratories Inc

    Sponsor: CSPC OUYI PHARM CO. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Oct 21, 2025approval313d agoTRAMADOL HYDROCHLORIDE — FDA approvalTrigen Laboratories Inc

    Sponsor: SUN PHARM. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →fda approvals ↗
    ›Oct 21, 2025approval313d agoTRAMADOL HYDROCHLORIDE — FDA approvaltramadol hydrochloride ER

    Sponsor: LUPIN LTD. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →tramadol hydrochloride ER →fda approvals ↗
    ›Oct 21, 2025approval313d agoOXYMORPHONE HYDROCHLORIDE — FDA approvalOXYMORPHONE HYDROCHLORIDE

    Sponsor: HIKMA. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →OXYMORPHONE HYDROCHLORIDE →fda approvals ↗
    ›Oct 21, 2025approval313d agoTRAMADOL HYDROCHLORIDE — FDA approvaltramadol hydrochloride ER

    Sponsor: STRIDES PHARMA INTL. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →tramadol hydrochloride ER →fda approvals ↗
    ›Oct 21, 2025approval313d agoSPEVIGO (SPESOLIMAB-SBZO) — FDA approvalspesolimab

    Sponsor: BOEHRINGER INGELHEIM PHARMACEUTICALS INC. Form: INJECTABLE. Route: INTRAVENOUS

    full page →spesolimab →fda approvals ↗
    ›Oct 21, 2025approval313d agoIMBRUVICA (IBRUTINIB) — FDA approvalAbbVie Inc.

    Sponsor: PHARMACYCLICS LLC. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Oct 21, 2025approval313d agoBLINCYTO (BLINATUMOMAB) — FDA approvalblinatumomab

    Sponsor: AMGEN. Form: INJECTABLE. Route: INJECTION

    full page →blinatumomab →fda approvals ↗
    ›Oct 21, 2025approval313d agoIMBRUVICA (IBRUTINIB) — FDA approvalAbbVie Inc.

    Sponsor: PHARMACYCLICS LLC. Form: SUSPENSION. Route: ORAL

    full page →fda approvals ↗
    ›Oct 21, 2025approval313d agoCELECOXIB — FDA approvalCelebrex

    Sponsor: LUPIN LTD. Form: CAPSULE. Route: ORAL

    full page →Celebrex →fda approvals ↗
    ›Oct 21, 2025approval313d agoTRIAMTERENE AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — FDA approvalChartwell Pharmaceuticals LLC

    Sponsor: PHARMOBEDIENT. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Oct 21, 2025approval313d agoTRIAMTERENE AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — FDA approvalChartwell Pharmaceuticals LLC

    Sponsor: PHARMOBEDIENT. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Oct 21, 2025approval313d agoCALCIUM CHLORIDE 10% (CALCIUM CHLORIDE) — FDA approvalCALCIUM CHLORIDE 10%

    Sponsor: AMNEAL. Form: INJECTABLE. Route: INJECTION

    full page →CALCIUM CHLORIDE 10% →fda approvals ↗
    ›Oct 21, 2025approval313d agoMIEBO (PERFLUOROHEXYLOCTANE) — FDA approvalBausch & Lomb Corp

    Sponsor: BAUSCH AND LOMB INC. Form: SOLUTION/DROPS. Route: OPHTHALMIC

    full page →fda approvals ↗
    ›Oct 21, 2025approval313d agoIMBRUVICA (IBRUTINIB) — FDA approvalAbbVie Inc.

    Sponsor: PHARMACYCLICS LLC. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Oct 21, 2025approval313d agoSUMATRIPTAN SUCCINATE — FDA approvalTonix Pharmaceuticals Holding Corp.

    Sponsor: PH HEALTH. Form: INJECTABLE. Route: SUBCUTANEOUS

    full page →fda approvals ↗
    ›Oct 21, 2025approval313d agoSTIMUFEND (PEGFILGRASTIM-FPGK) — FDA approvalSTIMUFEND

    Sponsor: FRESENIUS KABI USA. Form: SOLUTION. Route: INJECTION

    full page →STIMUFEND →fda approvals ↗
    ›Oct 21, 2025approval313d agoDEFERASIROX — FDA approvalDEFERASIROX

    Sponsor: ACTAVIS ELIZABETH. Form: TABLET, FOR SUSPENSION. Route: ORAL

    full page →DEFERASIROX →fda approvals ↗
    $AMGN432.42-1.05%
    $ARGX1058.90+1.13%
    $GKOS179.87-1.12%
    $AMRX17.54-2.61%
    $AZN164.52-1.05%
    $ARGX1058.90+1.13%
    $AZN164.52-1.05%
    $AMRX17.54-2.61%
    $BLCO17.13-0.70%
    $ABBV255.48-1.03%
    $TNXP13.56-0.59%
    $ABBV255.48-1.03%
    $ABBV255.48-1.03%
    $AMGN432.42-1.05%
    $NVS153.81-0.54%